GlassScriptPhysician profile
Jody S Berner
NPI 1245280395
$9,884.46
in general payments reported to CMS, 2019-2025
25 companies · $1,252 in 2025
The $1,252 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,052 · 2020: $4,356 · 2021: $376 · 2022: $750 · 2023: $1,078 · 2024: $1,020 · 2025: $1,252.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,350.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,349.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intercept Pharmaceuticals, INC. | $4,003.17 | 2020-2021 | |
| Abbvie INC. | $1,876.13 | 2019-2025 | Skyrizi, Linzess, Viberzi |
| Gilead Sciences, INC. | $724.57 | 2019-2025 | Livdelzi |
| Takeda Pharmaceuticals U.S.A., INC. | $398.31 | 2019-2023 | Entyvio |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $351.42 | 2019-2022 | |
| Medtronic, INC. | $317.97 | 2021-2024 | Interstim, Nexpowder |
| Janssen Biotech, INC. | $295.49 | 2019-2025 | Tremfya, Stelara, Simponi Aria |
| Boston Scientific Corporation | $267.71 | 2019-2023 | Interject, Compliance Endokit, Resolution Clip |
| Lilly USA, LLC | $206.58 | 2024-2025 | Omvoh |
| Aimmune Therapeutics, INC. | $177.73 | 2024-2025 | Vowst, Zenpep |
| Pfizer INC. | $155.34 | 2020-2024 | |
| Madrigal Pharmaceuticals | $147.19 | 2025 | Rezdiffra |
| E.R. Squibb & Sons, L.L.C. | $146.63 | 2023 | Zeposia |
| Genzyme Corporation | $140.25 | 2023 | |
| Evoke Pharma, INC. | $121.94 | 2023 | Gimoti |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $120.58 | 2019 | |
| Ardelyx, INC. | $120.10 | 2022 | |
| Celgene Corporation | $104.19 | 2022-2024 | Zeposia |
| Ironwood Pharmaceuticals, INC | $88.53 | 2019-2021 | |
| Mallinckrodt Hospital Products INC. | $38.59 | 2025 | Terlivaz |
| Braintree Laboratories, INC. | $20.52 | 2024 | Sutab, Suflave |
| Redhill Biopharma INC. | $20.31 | 2021 | |
| Fresenius Kabi USA, LLC | $15.09 | 2023 | |
| Merck Sharp & Dohme LLC | $14.36 | 2019 | |
| Ucb, INC. | $11.76 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jody Berner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.